Features of SARS-COV-2 infection and directions of drug and vaccine creation

Автор(и)

  • A. Yu. Volyansky Mechnikov Institute of Microbiology and Immunology,
  • T. V. Davydova Mechnikov Institute of Microbiology and Immunology,
  • M. V. Kuchma Mechnikov Institute of Microbiology and Immunology,
  • I. P. Yudin Mechnikov Institute of Microbiology and Immunology,
  • I. Yu. Kuchma Mechnikov Institute of Microbiology and Immunology,

Ключові слова:

SARS-CoV-2, genome, pathogenesis, therapeutic strategies

Анотація

Introduction: Until the beginning of the 21st century human coronaviruses were known as the cause of typical seasonal аcute respiratory disease. Highly pathogenic coronaviruses were identified as the cause of severe acute respiratory syndrome (SARS) with high mortality in 2002 – SARS-CoV, and then in 2013 as the causative agents of Middle East respiratory syndrome – MERS-CoV. They have caused severe respiratory disease in humans because of their ability to adapt to the host, increasing affinity for human airway receptors. The emergence a new coronavirus in 2019 caused a rapid increase in the incidence of severe acute respiratory syndrome and turned into a pandemic. Background: The new coronavirus SARS-CoV-2, which causes Covid-19 (coronavirus infection disease), was first detected in December 2019 in Wuhan, the capital of Hubei province, from where it quickly spread to China and continued to spread to Italy and other countries of Europe and after around the world, the number of confirmed new cases is increasing daily. Rationale: Coronaviruses are members of the order Nidovirales of the family Coronaviridae and divided into 4 genera: α- and β-coronavirus, which infect only mammals, and γ- and δ-coronavirus, which mainly affect birds. The central place is occupied by the genus β-coronavirus, which includes especially dangerous pathogens of lethal human pneumonia – SARS-CoV, MERS-CoV, SARS-CoV2. In turn, β-coronavirus divided into four subgenres: A, B, C, D. SARS-CoV-2 is β-coronavirus, subgroup B, Sarbecovirus. Coronaviruses affecting humans currently have 7 species. They divide into 2 groups. 1st group  has 4 common types of coronaviruses that cause about 15% of typical seasonal SARS: HCoV-229E, NL63, OC43 and HKU1. Usually these types cause mild forms of upper respiratory tract diseases in children (and less often in adults), but in some cases (like other SARS viruses) cause interstitial pneumonia (in newborns, children with immunodeficiency, people with cancer, patients who take immunosuppressive therapy, the elderly with heart failure and chronic lung disease). 2nd group has 3 types of coronaviruses, which in a large percentage of cases SARS. 1. SARS-CoV – the epidemic began in China in November 2002 from live animal markets in Foshan (Guangdong Province), spreading to Asia and the world. Considered, horseshoe bats can be the natural reservoir of SARS-CoV. SARS-CoV affected 32 countries for 9 months, 8096 people became ill, of which 774 died (9% mortality). No new cases of SARS-CoV have been report since 2004. 2. Another type of coronavirus that caused SARS in humans, MERS-CoV, first detected in Saudi Arabia in 2012. Сonsidered bats can be the natural reservoir of MERS-CoV, and single-humped camels can be vectors. MERS-CoV has been founding in patients in 27 countries, mainly in the Middle East, and remains endemic in many of them due to circulation in camels. The last outbreak of MERS occurred in South Korea in 2015, where the virus was imported from Kuwait (186 became ill and 33 died – the elderly). As of November 2019, MERS-CoV caused 858 deaths out of 2494 laboratory-confirmed cases (33% mortality). 3. SARS-CoV-2, like SARS-CoV and MERS-CoV, can cause severe respiratory disease with a high mortality rate. Horseshoe bats considered the natural reservoir of SARS-CoV2 (as well as SARS-CoV). There are two versions for SARS-CoV2: the first is that is bat coronavirus and it has spread from the seafood market, can crossed the interspecies barrier and become pathogenic to humans; second, that during an experiment at the Institute of Virology in Wuhan, the coronavirus accidentally struck an employee in an aerosol, who became the "first patient". Discussion: The virion of coronaviruses is covered with a lipid shell that clearly visible on electron microscopic images club-shaped spikes length of 10 nm. Coronaviruses contain a positive single-stranded RNA genome with a length of 26 to 32 thousand nucleotides (the largest known RNA virus) and four structural proteins – spike (S), envelope (E), membrane (M) and nucleocapsid (N). Protein S binds to target cell receptors and triggers the infectious process, protein M plays a role in shell formation and virion formation, and protein E forms pentameric ion channels that destroy cell membranes during viral budding. SARS-CoV-2 uses as receptors for cell penetration CD147 – glycoprotein and angiotensin converting enzyme type 2 (angiotensin converting enzyme 2 – ACE2). CD147 expressed in the cell membrane of epithelial and endothelial cells and T lymphocytes. Monoclonal antibodies against CD147 prevent infection of SARS-CoV2 cells in vitro. Analysis of cell samples for the presence of RNA sequences SARS-CoV-2 reveals significant RNA transcription in the nasal epithelium and less in the cells of the lower respiratory tract and alveolar epithelium. This suggests that the upper rather than the lower respiratory tract is the initial site of SARS-CoV-2 infection. ACE2 localized in type I and II pneumocytes, vascular endothelial cells and enterocytes (therefore symptoms from the respiratory tract are often accompanied by symptoms from the gastrointestinal tract – nausea, diarrhea, etc.). SARS-CoV2 infection leads to cytopathic effects, including apoptosis, cell lysis, and syncytium formation in lung tissue. After penetration into the host cell, the SARS-CoV-2 genome attaches to the ribosomes, leading to the translation of viral polyproteins, which subsequently processed by viral proteolytic enzymes. As a result, of proteolysis the protease-mediated virus 3CLpro (chymotrypsin-like protease) and PLpro (papain-like protease), polyproteins are broken down into smaller components, which plays a major role in mediating the replication and transcription of viruses and promotes infection. Another RdRp (RNA-dependent RNA-polymerase) enzyme, replicase, is important for viral genome replication and products of new virions. Therefore, these enzymes can considered as potential drug targets for the development of therapeutic agents, as they are crucial for the survival, replication and transmission of SARS-CoV-2. Therapeutic strategies is using for the treatment of Covid-19 mainly divided into immune and antiviral. S, E, M, N proteins, two replicase isoforms (RdRp1a and RdRp1ab) and proteases (3CLpro and PLpro) can be considere as potential targets for drugs and vaccines against SARS-CoV-2. Despite the many directions in the search the effective drugs for treatment Covid-19, today the most effective strategy in therapy is access to oxygen and well-staffed supportive care reduces mortality more than any medicinal product. Conclusion.  The sudden appearance of SARS-CoV-2 and the pandemic caused by this virus have posed a threat to the security of the global health system. The scientific community around the world is working hard to find effective drugs and vaccines against the new coronavirus. In an effort to find the cure for Covid-19, WHO has developed the SOLIDARITY concept, an international clinical trial as a common global platform for improving scientific links and accelerating information exchange. On the base of Mechnicov institute of microbiology and immunology National academy of medical sciences of Ukraine also began the study of the peculiarities of immunity Covid-19 for further development the therapeutic and vaccine strategies.

DOI: 10.5281/zenodo.4382122

Посилання

Cui J., Li F., Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019. N. 17. P. 181–192.

Li W., Zhang C., Sui J. et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 2005. N. 24. P. 1634–1643.

Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Ind J Pediatr. 2020. Vol. 87. N. 4. P. 281–6.

Wu F., Zhao S., Yu B. et al. A new Coronavirus associated with human respiratory disease in China. Nature. 2020. Vol. 579. P. 265–269.

Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020. doi.org/10.1001/jama.2020.2648.

Wang D., Hu B., Hu C. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. doi.org/10.1001/jama.2020.1585.

Mehra M.R., Desai S.S., Kuy S. et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. 2020. doi.org/10.1056/NEJMoa2007621.

Malik Y.S., Sircar S,. Bhat S. et al. Emerging novel coronavirus (2019-nCoV) – current scenario, evolutionary perspective based on genome analysis and recent developments Vet. Q. 2020. Vol. 40. P. 68–76.

Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020. Vol. 395. P. 497–506.

Li Q., Guan X., Wu P. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N. Engl. J. Med. 2020. Vol. 382. P. 1199–1207.

Weekly epidemiological update - 27 October 2020/Data as received by WHO from national authorities, as of 10am CEST 25/October/2020. .www.who.int/publications/m/item/weekly-epidemiological-update---27-october-2020

Chen Y., Liu Q., Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J. Med. Virol. 2020. Vol. 92. P. 418–423.

Wu A., Peng Y., Huang B. et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020. Vol. 27. P. 325–328.

Hanie Esakandari, Mohsen Nabi-Afjadi, Javad Fakkari-Afjadi. et al.A comprehensive review of COVID-19 characteristics. Biological Procedures Online 2020. Vol. 22. P. 217-234.

Lu R., Zhao X., Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020. Vol. 395. P. 565–574.

Zhang L., Lin D., Sun X. et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science. 2020. N. 14. P. 342-356.

Shamsi A., Mohammad T., Anwar S. et al. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy. Biosci Rep. 2020. N. 2. P. 540-552.

Graham R.L., Sparks J.S., Eckerle L.D. et al. SARS coronavirus replicase proteins in pathogenesis. Virus Res. 2008. Vol. 133. P. 88–100.

Shang J., Ye G., Shi K. et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020. Vol. 581. P. 221–224

Luk H.K.H., Li X., Fung J. et al. Molecular epidemiology, evolution and phylogeny of SARS coronavirus. Infect Genet Evol. 2019. Vol. 71. P. 21–30.

de Wit E., van Doremalen N., Falzarano D. et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016. N. 14. P. 523–34.

Brian DA, Baric RS. Coronavirus genome structure and replication . Curr Top Microbiol Immunol. 2005. Vol. 287. P. 1–30. CAS Central

Li C, Yang Y, Ren L. Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species . Infect Genet Evol. 2020. Vol. 82. P. 104-135. CAS

Minakshi R, Padhan K, Rehman S. et al.The SARS coronavirus 3a protein binds calcium in its cytoplasmic domain . Virus Res. 2014. Vol. 191. P. 180–183.

Nishikiori M, Sugiyama S, Xiang H. et al.Crystal structure of the superfamily 1 helicase from tomato mosaic virus . J. Virol. 2012. Vol. 86. P. 7565–7576.

van Dinten LC, van Tol H, Gorbalenya AE. et al.The predicted metal-binding region of the arterivirus helicase protein is involved in subgenomic mRNA synthesis, genome replication, and virion biogenesis . J. Virol. 2000. Vol. 74. P. 5213–5223.

von Grotthuss M, Wyrwicz LS, Rychlewski L. mRNA cap-1 methyltransferase in the SARS genome. Cell. 2003. Vol. 113. P. 701–702.

Zhao WM, Song SH, Chen ML. et al.The 2019 novel coronavirus resource . Yi Chuan. 2020. N. 42. P. 212–21.

Hodcroft EB, Zuber M, Nadeau S. Emergence and spread of a SARS-CoV-2 variant through Europe in the summer of 2020 . SeqCOVID-SPAIN consortium medRxiv preprint. doi: doi.org/10.1101/2020.10.25.20219063

Kuiken T, Fouchier RA, Schutten M. et al.Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome . Lancet. 2003. Vol. 362. P. 263–70. CAS Central

Zaki AM, van Boheemen S, Bestebroer TM. et al.Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia . N Engl J Med. 2012. Vol. 367. P. 1814–20. CAS

Ahmad Abu Turab Naqvi, Kisa Fatima, Taj Mohammad. et al.Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach . Biochim Biophys Acta Mol Basis Dis. 2020. Oct 1. Vol. 1866. N. 10. P. 165878. Published online 2020 Jun 13. doi: 10.1016/j.bbadis.2020.165878 PMCID: PMC7293463 PMID: 32544429

Hamming I, Timens W, Bulthuis MLC. et al.Tissue distribution of ACE2 protein, the functional receptor for SARS Coronavirus . J Pathol 2004. Vol. 203. P. 631–637. CAS Central

Li M-Y, Li L, Zhang Y. et al.Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues . Infect Dis Poverty 2020. N. 9. P. 45. Central

Hamming I, Timens W, Bulthuis MLC. et al.A first step in understanding SARS pathogenesis . J Pathol 2004. Vol. 203. P. 631–637. CAS Central

Xiao H-L, Zhao L-X, Yang J. et al.Association between ACE2/ACE balance and pneumocyte apoptosis in a porcine model of acute pulmonary thromboembolism with cardiac arrest . Mol Med Rep. 2018. Vol. 17. N. 3. P. 4221–8. CAS Central

Lamers MM, Beumer J, van der Vaart J. et al.SARS-CoV-2 productively infects human gut enterocytes . Science. 2020. doi: doi.org/10.1126/science.abc1669

Zhu H, Rhee JW, Cheng P. et al.Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response . Curr Cardiol Rep. 20. Vol. 22. N. 5. P. 32-48. Central

Wrapp D, Wang N, Corbett KS. et al.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation . Science. 2020. Vol. 367. P. 1260–1263.

Suzuki T, Otake Y, Uchimoto S. et al.Genomic characterization and phylogenetic classification of bovine coronaviruses through whole genome sequence analysis . Viruses. 2020. N. 12. P. 183.

Lu R, Wang Y, Wang W. et al.Complete genome sequence of Middle East respiratory syndrome coronavirus (MERS-CoV) from the first imported MERS-CoV case in China . Genome Announc. 2015. N. 3. P. 26-34. (e00818-00815)

Yeshun Wu, Xiaolin Xu, Zijun Chen. et al.Nervous system involvement after infection with COVID-19 and other coronaviruses . Brain Behav Immun. 2020 Jul. Vol. 87. P. 18–22. doi: 10.1016/j.bbi.2020.03.031 PMCID: PMC7146689 PMID: 32240762

Pallanti S. Importance of SARs-Cov-2 anosmia: From phenomenology to neurobiology . Compr Psychiatry. 2020. Jul. Vol. 100. P. 152184. doi:10.1016/j.comppsych.2020.152184. Epub 2020 May11. PMID: 32422426

Ellul MA, Benjamin L, Singh B. et al.. Neurological associations of COVID-19 . Lancet Neurol. 2020. Sep. Vol. 19. N. 9. P. 767-783. doi: 10.1016/S1474-4422(20)30221-0. Epub 2020 Jul 2. PMID: 32622375

Payus AO, Liew Sat Lin C, Mohd Noh M. et al.SARS-CoV-2 infection of the nervous system: A review of the literature on neurological involvement in novel coronavirus disease-(COVID-19) . J Basic Med Sci. 2020. Aug 3. Vol. 20. N. 3. P. 283-292. doi:10.17305/bjbms.2020.4860. PMID: 32530389

Morse JS, Lalonde T, Xu S. et al.Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV . Chembiochem. 2020. Vol. 21. P. 730–738.

Zhang H, Zhou P, Wei Y. et al.Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19 .Ann Intern Med. 2020. May 5. Vol. 172. N. 9. P. 629-632. doi: 10.7326/M20-0533. Epub 2020 Mar 12.

PMID: 32163542 Free PMC article.

Xu YH, Dong JH, An WM. et al.Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2 . J Infect. 2020 Apr. Vol. 80. N. 4. P. 394-400. doi: 10.1016/j.jinf.2020.02.017. Epub 2020 Feb 25. PMID: 32109443 Free PMC article

Wichmann D, Sperhake JP, Lütgehetmann M. et al.Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study . Ann Intern Med. 2020 Aug 18. Vol. 173. N. 4. P. 268-277. doi: 10.7326/M20-2003. Epub 2020 May 6. PMID: 32374815 Free PMC article.

Imai Y, Kuba K, Rao S. et al.Angiotensin-converting enzyme 2 protects from severe acute lung failure . Nature. 2005. Vol. 436. P. 112–6. CAS Central

Taisheng L, Zhifeng Q, Linqi Z. et al.Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome . J Infect Dis. 2004. Vol. 189. N. 4. P. 648–651. doi: 10.1086/381535 CrossRef

Liu Z Y, Li T S, Wang Z. et al.Clinical features and therapy of 106 cases of severe acute respiratory syndrome . Chinese J Intern Med. 2003. N. 06. P. 16–20.

Li TS, Qiu ZF, Han Y et al.The alterations of T cell subsets of severe acute respiratory syndrome during acute phase . Chinese J Lab Med. 2003. N. 05. P. 40–42.

Xie J, Fan HW, Li TS et al.Dynamic changes of T lymphocyte subsets in the long-term follow-up of severe acute respiratory syndrome patients . Chinese Acad Med Sci. 2006. Vol. 28. N. 2. P. 253–255.

Gang L, Chen MJ, Chen W. et al.Variation in the titer of the specific IgG antibody in patients with SARS . J Trop Med. 2003. N. 03. N. 283–285.

Cao Z, Liu L, Du L. et al.Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients . Virol J. 2010. Vol. 7. N. 1. P. 299. doi: 10.1186/1743-422X-7-299 CrossRef

Stockman LJ, Bellamy R, Garner P. SARS: Systematic review of treatment effects . PLoS Med. 2006. Vol. 3. N. 9. e343. doi: 10.1371/journal.pmed.0030343 CrossRef

Cameron MJ, Ran L, Xu L. et al.Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome . J Virol. 2007. Vol. 81. P. 8692–706. CAS Central

Cameron MJ, Bermejo-Martin JF, Danesh A. et al.Human immunopathogenesis of severe acute respiratory syndrome (SARS) . Virus Res. 2008. Vol. 133. P. 13–9. CAS

Raj VS, Mou H, Smits SL. et al.Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC . Nature. 2013. Vol. 495(7440). P. 251–254. doi: 10.1038/nature12005 CrossRef

Li W, Moore MJ, Vasilieva N. et al.Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus . Nature. 2003. Vol. 426(6965) P. 450–454. doi: 10.1038/nature02145 CrossRef

Ko JH, Park GE, Lee JY. et al.Predictive factors for pneumonia development and progression to respiratory failure in MERS-CoV infected patients . J Infect. 2016. Vol. 73. P. 468–475. doi: 10.1016/j.jinf.2016.08.005 CrossRef

Min CK, Cheon S, Ha NY. et al.Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity . Sci Rep. 2016. N. 6. P. 25359. doi: 10.1038/srep25359 CrossRef

Zumla A, Hui DS, Perlman S. et al.Middle East respiratory syndrome . Lancet. 2014. Vol. 40. N. 7. P. 995–1007.

Alosaimi B, Hamed ME, Naeem A. et al.MERS-CoV infection is associated with downregulation of genes encoding Th1 and Th2 cytokines/chemokines and elevated inflammatory innate immune response in the lower respiratory tract . Cytokine. 2020;126:154895. doi: 10.1016/j.cyto.2019.154895 CrossRef

Shin HS, Kim Y, Kim G. et al.Immune responses to Middle East respiratory syndrome coronavirus during the acute and convalescent phases of human infection . Clin Infect Dis. 2019. Vol. 68. P. 984–992. doi: 10.1093/cid/ciy595 CrossRef

Stohlman SA, Bergmann CC, Veen RCVD. et al.Mouse hepatitis virus-specific cytotoxic T lymphocytes protect from lethal infection without eliminating virus from the central nervous system . J Virol. 1995. Vol. 69. N. 2. P. 684–694. doi: 10.1128/JVI.69.2.684-694.1995 CrossRef

Zhao J, Alshukairi AN, Baharoon S A. et al.Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses . Sci Imm. 2017. N. 2(14). undefined.

Bautista E, Chotpitayasunondh T, Gao ZC. et al.Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection . N Engl J Med. 2010. Vol. 362. N. 18. P. 1708–1719. doi: 10.1056/NEJMra1000449 CrossRef

Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. . J Autoimmun. 2020. N. 4. P. 102433.

Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) . Biosci Trends. 2020. Vol. 14. N. 1. P. 69–71. CAS

Nikolich-Zugich J. The twilight of immunity: emerging concepts in aging of the immune system . Nat Immunol. 2018. Vol. 19. P. 10–9. CAS

Solana R, Pawelec G, Tarazona R. Aging and innate immunity . Immunity. 2006. N. 24. P. 491–4.

Goronzy JJ, Li G, Yu M, Weyand CM. Signaling pathways in aged T cells – a reflection of T cell differentiation, cell senescence and host environment . Semin Immunol. 2012. Vol. 24. P. 365–72.

Kogut I, Scholz JL, Cancro MP. [et at.] B cell maintenance and function in aging . Semin Immunol. 2012. Vol. 24. P. 342–9. CAS

Chinn IK, Blackburn CC, Manley NR. et al.Changes in primary lymphoid organs with aging . Semin Immunol. 2012;24:309–20. CAS Central

Naylor K, Li G, Vallejo AN. et al.The influence of age on T cell generation and TCR diversity . J Immunol. 2005. Vol. 174. P. 7446–52. CAS

Thompson HL, Smithey MJ, Surh CD. et al.Functional and homeostatic impact of age-related changes in lymph node stroma . Front Immunol. 2017. N. 8. P. 706. Central

Richner JM, Gmyrek GB, Govero J. et al.Age-dependent cell trafficking defects in draining lymph nodes impair adaptive immunity and control of west nile virus infection . PLoS Pathog. 2015. N. 11. P. 5027.

Brien JD, Uhrlaub JL, Hirsch A. et al.Key role of T cell defects in age-related vulnerability to West Nile virus . J Exp Med. 2009. Vol. 206. P. 2735–45. CAS Central

Smithey MJ, Renkema KR, Rudd BD. et al.Increased apoptosis, curtailed expansion and incomplete differentiation of CD8(+) T-cells combine to decrease clearance of L. monocytogenes in old mice . Eur J Immunol. 2011. Vol. 41. P. 1352–64

Ledford H. Coronavirus shuts down trials of drugs for multiple other diseases . Nature. 2020. Vol. 580. P. 15–16.

Du L, He Y, Zhou Y. et al.The spike protein of SARS-CoV – a target for vaccine and therapeutic development . Nat. Rev. Microbiol. 2009. N. 7. P. 226–236.

Liu C, Zhou Q, Li Y. et al.Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases . ACS Cent Sci. 2020. N. 6. P. 315–331.

Guastalegname M, Vallone A. Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment? . Clin. Infect. Dis. 2020. P. 321.

Zumla A, Chan JF, Azhar EI. et al.Coronaviruses – drug discovery and therapeutic options . Nat. Rev. Drug Discov. 2016. N. 15. P. 327–347.

Gao Y, Yan L, Huang Y. et al.Structure of the RNA-dependent RNA polymerase from COVID-19 virus . Science. 2020. Vol. 254. P. 504-534.

Wang M, Cao R, Zhang L. et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro . Cell Res. 2020. Vol. 30. P. 269–271.

Wang Y, Zhang D, Du G. et al.Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial . The Lancet. 2020. Vol. 395. P. 1569–1578.

Schlagenhauf P, Grobusch MP, Maier JD. et al.Repurposing antimalarials and other drugs for COVID-19 . Travel Med. Infect. Dis. 2020. Vol. 34. P. 101658.

Huang M, Tang T, Pang P. et al.Treating COVID-19 with chloroquine . J Mol Cell Biol. 2020. N. 12. P. 322–325.

Hong W. Combating COVID-19 with chloroquine. . J Mol Cell Biol. 2020. N. 12. P. 249–250.

Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies . Bioscience Trends. 2020. N. 14. P. 72–73.

Liu J, Cao R, Xu M. et al.Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro . Cell Discovery. 2020. N. 6. P. 16.

FitzGerald GA. Misguided drug advice for COVID-19 . Science. 2020. Vol. 367. P. 1434.

South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences . Am. J. Phys. Heart Circ. Phys. 2020. Vol. 318. P. 1084–1090.

Huang GJ, Xu, Liu J. et al.Zhang, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis . Eur. J. Clin. Investig. 2011. Vol. 41. P. 719–733.

Zhang P, Zhu L, Cai J. et al.Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19 . Circ. Res. 2020. Vol. 126. P. 142–143.

Grein J, Ohmagari N, Shin D. Compassionate use of remdesivir for patients with severe Covid-19 . N Engl J Med. 2020. Vol. 382:2327–2336.

Cao X. COVID-19: immunopathology and its implications for therapy . Nat Rev Immunol. 2020. N. 20. P. 269–270.

Xu X, Han M, Li T. Effective treatment of severe COVID-19 patients with tocilizumab . Proc. Natl. Acad. Sci. U. S. A. 2020. Vol. 117. P. 10970–10975.

Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal stem cell therapy for COVID-19: present or future . Stem Cell Rev. Rep. 2020. P. 1–7.

Shen C, Wang Z, Zhao F. et al.Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020. Vol. 323. P. 1582–1589.

Chen L, Xiong J, Bao L. et al.Convalescent plasma as a potential therapy for COVID-19 . Lancet Infect. Dis. 2020. N. 20. P. 398–400.

Duan YJ, Liu Q, Zhao S.Q. et al.The Trial of Chloroquine in the Treatment of Corona Virus Disease COVID-19 and its research progress in forensic toxicology . Fa Yi Xue Za Zhi. 2019. Vol. 36(2020)

Bhatnagar T, Murhekar MV, Soneja M. et al.Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: protocol for restricted public health emergency use . Indian J. Med. Res. 2020. Vol. 151. P. 184–189.

Day M. Covid-19: European drugs agency to review safety of ibuprofen . BMJ. 2020. Vol. 368. P. 1168.

Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use . Pain Physician. 2020. N. 23. P. 71–83.

Monk PD, Marsden RJ, Tear VJ. et al.Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial . Lancet Respir Med 12.11.2020. P. 1-11. doi.org/10.1016/S2213-2600(20)30511-7 .www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30511-7/fulltext

Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics . Drug Dev. Res. 2020. doi: 10.1002/ddr.21656. In preparation. CrossRef

Pan H, Peto R, Quarraisha AK. et al.Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results . MedRxiv. 15.10.2020. doi: doi.org/10.1101/2020.10.15.20209817

Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? . Int. J. Mol. Sci. 2020. N. 21. P. 2272.

Ma J, Xia P, Zhou Y. et al.Potential effect of blood purification therapy in reducing cytokine storm as a late complication of severe COVID-19 . Clinical Immunology (Orlando, Fla.) 2020. Vol. 140. P. 108408.

Luo P, Liu Y, Qiu L. et al.Tocilizumab treatment in COVID-19: a single center experience . J. Med. Virol. 2020. Vol. 92. P. 814–818.

Shamsi A, Mohammad T, Anwar S. et al.Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy . Bioscience Reports. 2020 Vol. 40. BSR20201256.

Beigel JH, Tomashek RM, Dodd LE. et al.Remdesivir for the Treatment of Covid-19 — Final Report . N Engl J Med 05.11.2020. V. 383. P. 1813-1826. doi: doi.org/10.1056/NEJMoa2007764

Siemieniuk RAC, Bartoszko JJ, Long Ge. et al.Drug treatments for covid-19: living systematic review and network meta-analysis . BMJ 2020. V. 370. .www.bmj.com/content/370/bmj.m2980

Horby P, Landray M. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. The RECOVERY Collaborative Group . Recovery. 05.06.2020.

.www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf

Horby P, Wei Shen Lim, Landray M. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. The RECOVERY Collaborative Group . N Engl J Med 16.11.2020. V. 383. P. 1-11. .www.nejm.org/doi/10.1056/NEJMoa2021436

Stone JH, Frigault MT, Serling-Boyd NJ. et al.Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 . N Engl J Med. 21.10.2020..www.nejm.org/doi/full/10.1056/NEJMoa2028836

Chen WH, Strych U, Hotez PJ. et al.The SARS-CoV-2 vaccine pipeline: an overview . Curr Trop Med Rep. 2020. P. 1–4.

##submission.downloads##

Як цитувати

Volyansky, A. Y., Davydova, T. V., Kuchma, M. V., Yudin, I. P., & Kuchma, I. Y. (2020). Features of SARS-COV-2 infection and directions of drug and vaccine creation. Анали Мечниковського Інституту, (4), 7–20. вилучено із https://journals.uran.ua/ami/article/view/220161

Номер

Розділ

Огляди